Screener / SEC EDGAR /CIK 0001906324 /10-K filed Feb 19, 2026, compared with Feb 27, 2025 /Numbers from the XBRL of the 10-Ks
Health care peers:
Nasdaq Health care · Diagnostics

QuidelOrtho Corp QDEL

Our vision is to advance diagnostics to power a healthier future. 10-K, Item 1

Employees
6,500
Headquarters
San Diego, CA
CEO
Brian J. Blaser
Next results
around Feb 10, 2027
Compare with peers Embed

QDEL among Health care peers

Six ratios from the latest 10-K. Each corner is the share of 154 peers the company is above, not a score.

Compare
Revenue growth: -1.9%, above 9% of 154 peers (their median 10.5%) REVENUE GROWTH -1.9% · above 9% Operating margin: -4.9%, above 23% of 138 peers (their median 10.2%) OPERATING MARGIN -4.9% · above 23% Net margin: -14.2%, above 18% of 153 peers (their median 6.8%) NET MARGIN -14.2% · above 18% FCF margin: -4.5%, above 17% of 144 peers (their median 10.1%) FCF MARGIN -4.5% · above 17%
QDEL Peer median Below the median

What changed

10 new risk paragraphs and 3 accounting facts worth reading about. 10-K filed Feb 19, 2026 against Feb 27, 2025.

Each row opens the detail with the quote and the filing. A row is a change worth reading, not a verdict.

Accounting checks

11 checks on the latest 10-K. Checks, not verdicts.

How it works

3facts worth reading about the other 8 checks found nothing to note

  • Receivables growing faster than revenue
    Receivables +47.7% ($282.4M to $417.0M) vs revenue -1.9% ($2.8B to $2.7B), +49.6 pts apart
  • Inventory growing faster than revenue
    Inventory +8.2% ($533.7M to $577.6M) vs revenue -1.9% ($2.8B to $2.7B), +10.1 pts apart
  • Auditor change
    8-K item 4.01 (change in certifying accountant) filed Mar 4, 2025
  • Cash from operations $105.2M vs net income −$1.1B (FY ending Dec 28, 2025)
7 more checks with nothing to note
  • No statement of substantial doubt about going concern
  • No 8-K item 4.02 in the last 2 years
  • No NT 10-K or NT 10-Q in the last 2 years
  • The same matters as last year: Allowance for contractual rebates; Goodwill impairment assessment
  • No sentence in the 10-K concludes that controls were not effective because of a material weakness
  • No 8-K item 2.06 in the last 2 years
  • No 8-K item 1.03 in the last 2 years

In their words

10 paragraphs in Risk Factors that were not in the 10-K filed Feb 27, 2025. Quoted as filed.

All 10 new paragraphs
  1. Item 1A · new paragraph · not in the 10-K filed Feb 27, 2025 10-K, ITEM 1A
    Our collaboration arrangements may not operate according to our business strategy and if we are unable to maintain our collaboration arrangements, or if these collaboration arrangements are not successful, our results of operations could be materially adversely affected.
  2. Item 1A · new paragraph · not in the 10-K filed Feb 27, 2025 10-K, ITEM 1A
    We may engage in strategic transactions, including acquisitions, investments, joint ventures, licensing arrangements and other strategic relationships, undertake strategic restructurings or divest, spin-off or discontinue certain business operations, and may not successfully identify or consummate these strategic transactions;…
  3. Item 1A · new paragraph · not in the 10-K filed Feb 27, 2025 10-K, ITEM 1A
    We may also undertake initiatives to restructure or streamline our operations in order to achieve cost savings and improve operational efficiency. For example, in the second quarter of 2025, we launched the Optimization Plan that aims to (i) realign our costs with our long-term revenue expectations, (ii) drive operational efficiencies…
  4. Item 1A · new paragraph · not in the 10-K filed Feb 27, 2025 10-K, ITEM 1A
    Outside the U.S., commercialization is subject to diverse and evolving regulatory regimes, including, for example, the EU IVDR, Health Canada licensing and the NMPA in China. These regulatory regimes may require local clinical evidence, language- and country-specific labeling, post-market surveillance and vigilance reporting, and…

New risk paragraphs, against peers

Latest 10-K of each, Health care companies closest in revenue

Paragraphs in Risk Factors with nothing like them in the company's 10-K the year before. A count of text, not of risk.

Financial performance

Last 4 fiscal years · 10-K XBRL

All years
MetricFY2022FY2023FY2024FY2025
Revenue$3.3B$3.0B$2.8B$2.7B
Net income$548.7M−$10.1M−$2.1B−$1.1B
Operating cash flow$885.3M$280.2M$83.0M$105.2M
Free cash flow$744.4M$70.9M−$112.1M−$83.0M

Revenue, FY2020 to FY2025

Ten fiscal years, each from its own 10-K · XBRL · USD

$2.7B ▼ 1.9% in FY2025

FY2020FY2021FY2022FY2023FY2024FY2025
Every number, year by year

Recent filings

2 filings in the last 30 days · SEC EDGAR

All filings

About the company

QuidelOrtho Corp, San Diego, CA · from the 10-K filed Feb 19, 2026

Our vision is to advance diagnostics to power a healthier future. With our expertise in immunoassay and molecular testing, clinical chemistry and transfusion medicine, we aim to support clarity for clinicians and patients to help create better health outcomes. Our global infrastructure and commercial reach support our customers across more than 140 countries and territories with quality diagnostics, a broad test portfolio and market-leading service. We operate globally with manufacturing facilities in the U.S., U.K. and China and with sales centers, administrative offices and warehouses located throughout the world.

Headquarters
San Diego, CA
Country
United States
Reports in
USD
Listed on
Nasdaq
Fiscal year ends
January 1
Last results
Nov 3, 2026

Employees, at the top of the page: "As of December 28, 2025, we had approximately 6,500 employees worldwide, with approximately 3,600 employees in the U" (10-K). Address and exchange: SEC's company file.

Email alerts

Sources

The 10-K filed Feb 19, 2026 (open at SEC), compared with the 10-K filed Feb 27, 2025. Numbers from the XBRL of the 10-Ks; filings from SEC EDGAR.

Work with it: Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/QDEL/export.csv") into a cell.

Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.